Compare Open Text Corporation (OTEX) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Open Text Corporation vs Viatris Inc — how do they compare? Open Text Corporation trades at $22.41 (market cap $5.54B), while Viatris Inc trades at $17.02 (market cap $20.50B). The key difference: Viatris Inc is far larger — about 3.7× Open Text Corporation's market cap, and Open Text Corporation pays the higher dividend (4.83%). Which is the better fit depends on your goals.
| OTEX | VTRS | |
|---|---|---|
Market Cap | $5.54B | $20.50B |
Sector | Technology | Health |
52-Week High | $39.69 | $17.59 |
52-Week Low | $20.01 | $8.74 |
Enterprise Value | $10.70B | $32.71B |
Dividend Yield | 4.83% | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Open Text Corporation (OTEX) trades at $23.33, up 0.26% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $1.01 surpassing expectations. Fundamentals show a P/E of 11.32 and net income margin of 9.91%, while recent news highlights a $105 million investment in European AI and cloud expansion.
The outlook for OTEX is positive, supported by value-oriented valuation, consistent earnings outperformance, and strategic investments in AI. Key risks include competitive pressures in software and execution of growth initiatives. Analyst consensus suggests a 30.7% upside to the $29.75 price target, with 42% of ratings being Buy.
Viatris (VTRS) trades at $17.59, up 1.74% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3B for 2025 but posted a net loss of $3.51B, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a PDUFA date set for December 2026. Cash flow from operations remains strong at $2.32B, supporting debt reduction efforts.
The outlook is mixed: analyst consensus targets $20.00 (13.7% upside), but profitability challenges and high debt levels pose risks. Investment appeal hinges on successful pipeline execution and margin recovery, while competitive and regulatory pressures in the generics market remain key watchpoints for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Open Text Corporation
Open Text Corporation is a global leader in Enterprise Information Management (EIM) software and solutions. The company provides a comprehensive platform that helps organizations manage, secure, and leverage their unstructured digital content, including documents, emails, and media files. OTEX's offerings span content management, business process management, customer experience management, and security, serving large enterprises across various industries worldwide.
Read more on OTEX →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
